These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. Chen LN; Carvajal RD Expert Rev Anticancer Ther; 2022 Oct; 22(10):1017-1027. PubMed ID: 36102132 [TBL] [Abstract][Full Text] [Related]
4. Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma. Damato BE; Dukes J; Goodall H; Carvajal RD Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31336704 [TBL] [Abstract][Full Text] [Related]
5. Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma. Wang Z; Xie Y; Wang JQ; Cheng Y; Fleishman J; Chen ZS; Chen Y Drugs Today (Barc); 2023 Mar; 59(3):179-193. PubMed ID: 36847626 [TBL] [Abstract][Full Text] [Related]
6. T Cell-Engaging Bispecific Antibodies Targeting gp100 and PRAME: Expanding Application from Uveal Melanoma to Cutaneous Melanoma. Reschke R; Enk AH; Hassel JC Pharmaceutics; 2024 Aug; 16(8):. PubMed ID: 39204391 [TBL] [Abstract][Full Text] [Related]
7. Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors. Liu AW; Wei AZ; Maniar AB; Carvajal RD Expert Opin Biol Ther; 2022 Aug; 22(8):997-1004. PubMed ID: 35060440 [TBL] [Abstract][Full Text] [Related]
8. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. Nathan P; Hassel JC; Rutkowski P; Baurain JF; Butler MO; Schlaak M; Sullivan RJ; Ochsenreither S; Dummer R; Kirkwood JM; Joshua AM; Sacco JJ; Shoushtari AN; Orloff M; Piulats JM; Milhem M; Salama AKS; Curti B; Demidov L; Gastaud L; Mauch C; Yushak M; Carvajal RD; Hamid O; Abdullah SE; Holland C; Goodall H; Piperno-Neumann S; N Engl J Med; 2021 Sep; 385(13):1196-1206. PubMed ID: 34551229 [TBL] [Abstract][Full Text] [Related]
9. Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations. Montazeri K; Pattanayak V; Sullivan RJ Drug Des Devel Ther; 2023; 17():333-339. PubMed ID: 36785760 [TBL] [Abstract][Full Text] [Related]
10. Tebentafusp: First Approval. Dhillon S Drugs; 2022 Apr; 82(6):703-710. PubMed ID: 35364798 [TBL] [Abstract][Full Text] [Related]
11. Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report. Reiter S; Schroeder C; Broche J; Sinnberg T; Bonzheim I; Süsskind D; Flatz L; Forschner A Front Oncol; 2023; 13():1167791. PubMed ID: 37207136 [TBL] [Abstract][Full Text] [Related]
12. Tebentafusp for the treatment of metastatic uveal melanoma. Schank TE; Hassel JC Future Oncol; 2022 Apr; 18(11):1303-1311. PubMed ID: 35172589 [TBL] [Abstract][Full Text] [Related]
13. Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. Middleton MR; McAlpine C; Woodcock VK; Corrie P; Infante JR; Steven NM; Evans TRJ; Anthoney A; Shoushtari AN; Hamid O; Gupta A; Vardeu A; Leach E; Naidoo R; Stanhope S; Lewis S; Hurst J; O'Kelly I; Sznol M Clin Cancer Res; 2020 Nov; 26(22):5869-5878. PubMed ID: 32816891 [TBL] [Abstract][Full Text] [Related]
14. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. Hassel JC; Piperno-Neumann S; Rutkowski P; Baurain JF; Schlaak M; Butler MO; Sullivan RJ; Dummer R; Kirkwood JM; Orloff M; Sacco JJ; Ochsenreither S; Joshua AM; Gastaud L; Curti B; Piulats JM; Salama AKS; Shoushtari AN; Demidov L; Milhem M; Chmielowski B; Kim KB; Carvajal RD; Hamid O; Collins L; Ranade K; Holland C; Pfeiffer C; Nathan P N Engl J Med; 2023 Dec; 389(24):2256-2266. PubMed ID: 37870955 [TBL] [Abstract][Full Text] [Related]
15. Review of bi-specific therapies in uveal melanoma. Orloff M; Seedor R; Sato T Cancer Gene Ther; 2022 Dec; 29(12):1814-1818. PubMed ID: 35236927 [TBL] [Abstract][Full Text] [Related]
16. Tumor lysis syndrome induced by tebentafusp. Ruf T; Leonhardt A; Anz D; Kunz WG; Röhrle N; Foerster P; Tomsitz D; French LE; Seegräber M; Heinzerling L Immunotherapy; 2023 Nov; 15(16):1363-1368. PubMed ID: 37661909 [TBL] [Abstract][Full Text] [Related]
17. Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond. Gerard C; Shum B; Nathan P; Turajlic S Immunooncol Technol; 2023 Sep; 19():100386. PubMed ID: 37483658 [TBL] [Abstract][Full Text] [Related]
18. Tebentafusp in first-line melanoma trials: An outperforming outlier. Olivier T; Prasad V Transl Oncol; 2022 Jun; 20():101408. PubMed ID: 35364557 [TBL] [Abstract][Full Text] [Related]
19. Tebentafusp: a first-in-class treatment for metastatic uveal melanoma. Howlett S; Carter TJ; Shaw HM; Nathan PD Ther Adv Med Oncol; 2023; 15():17588359231160140. PubMed ID: 36970111 [TBL] [Abstract][Full Text] [Related]
20. Successful application of chemosaturation with percutaneous hepatic perfusion in metastatic uveal melanoma patient progressing after systemic treatment options: a case report. Gunenc D; Ozluk AA; Yıldırım UM; Ascierto PA; Karaca B Front Oncol; 2024; 14():1355971. PubMed ID: 38660135 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]